Copyright
©The Author(s) 2021.
World J Gastrointest Oncol. Oct 15, 2021; 13(10): 1532-1543
Published online Oct 15, 2021. doi: 10.4251/wjgo.v13.i10.1532
Published online Oct 15, 2021. doi: 10.4251/wjgo.v13.i10.1532
Table 4 Survival outcomes
| Time | DFS (95%CI) | OS (95%CI) | LRFS (95%CI) | DMFS (95%CI) |
| 3 yr | 66.2 (58.6-73.8) | 75 (68.2-81.8) | 80.8 (74.2-88.6) | 72.4 (64.9-79.9) |
| 5 yr | 55.2 (47.1-63.3) | 58.9 (51.0-66.8) | 80.8 (74.2-88.6) | 60.4 (52.1-68.7) |
| 7 yr1 | 52.3 (44.1-60.5) | 48.2 (39.5-56.9) | 80.8 (74.2-88.6) | 57.2 (48.8-65.6) |
- Citation: Wang X, Wang WH, Wang SL, Song YW, Liu YP, Tang Y, Li N, Liu WY, Fang H, Li YX, Zhao DB, Chi Y, Yang L, Jin J. Efficacy and toxicity of capecitabine combined with intensity-modulated radiotherapy after D1/D2 lymph node dissection in patients with gastric cancer. World J Gastrointest Oncol 2021; 13(10): 1532-1543
- URL: https://www.wjgnet.com/1948-5204/full/v13/i10/1532.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v13.i10.1532